Brookline Capital Markets Says Its Time To Buy Rexahn Pharma (AMEX:RNN). Will Stock Hit Their Target of $10.0000?

Why Has Brookline Capital Markets Given Rexahn Pharma (AMEX:RNN) a $10.0000 Price Target

Brookline Capital Markets analyst began coverage on Rexahn Pharma (AMEX:RNN) with a $10.0000 TP and Buy rating. The TP suggests a potential upside of 825.93 % from company’s last stock close price.

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) Ratings Coverage

Among 2 analysts covering Rexahn Pharma (AMEX:RNN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rexahn Pharma has $19.5000 highest and $1000 lowest target. $14.75’s average target is 1265.74% above currents $1.08 stock price. Rexahn Pharma had 3 analyst reports since June 4, 2018 according to SRatingsIntel. Brookline Capital Markets initiated the stock with “Buy” rating in Tuesday, November 27 report. The rating was maintained by H.C. Wainwright on Monday, June 4 with “Buy”.

The stock decreased 1.82% or $0.02 during the last trading session, reaching $1.08. About 137,517 shares traded. Rexahn Pharmaceuticals, Inc. (AMEX:RNN) has declined 32.14% since December 2, 2017 and is downtrending. It has underperformed by 47.76% the S&P500.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company has market cap of $40.52 million. The company's clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It currently has negative earnings. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma.

More notable recent Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) news were published by: which released: “Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting – GlobeNewswire” on January 22, 2018, also with their article: “Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin?) for the treatment of Hepatocellular Carcinoma – GlobeNewswire” published on February 08, 2018, published: “Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference – GlobeNewswire” on August 30, 2018. More interesting news about Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) were released by: and their article: “Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting – GlobeNewswire” published on February 05, 2018 as well as‘s news article titled: “Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018 – GlobeNewswire” with publication date: January 08, 2018.

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.